DexCom, Inc.
DXCM
Classement en actions
#770
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Prix de l'action
$83.01
Capitalisation boursière
$31.32B
Changement (1 jour)
-3.19%
Changement (1 an)
19.01%
Pays
US
Échange DexCom, Inc. (DXCM)
Catégorie
Healthcare
Revenus pour DexCom, Inc. (DXCM)
Revenus en Jun 2026 TTM : $4.97B
Selon les derniers rapports financiers de DexCom, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $4.97B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $4.03B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $3.62B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour DexCom, Inc. de 2000 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $4.97B | 6.59% |
| 2025 | $4.66B | 15.60% |
| 2024 | $4.03B | 11.34% |
| 2023 | $3.62B | 24.49% |
| 2022 | $2.91B | 18.84% |
| 2021 | $2.45B | 27.08% |
| 2020 | $1.93B | 30.54% |
| 2019 | $1.48B | 43.08% |
| 2018 | $1.03B | 43.58% |
| 2017 | $718.50M | 25.33% |
| 2016 | $573.30M | 42.61% |
| 2015 | $402.00M | 55.09% |
| 2014 | $259.20M | 62.00% |
| 2013 | $160.00M | 60.16% |
| 2012 | $99.90M | 30.99% |
| 2011 | $76.27M | 56.83% |
| 2010 | $48.63M | 63.78% |
| 2009 | $29.69M | 201.82% |
| 2008 | $9.84M | 112.62% |
| 2007 | $4.63M | 113.25% |
| 2006 | $2.17M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $46.59B | 837.47% |
US
|
|
| $35.48B | 614.08% |
IE
|
|
| $25.84B | 419.94% |
US
|
|
| $21.00B | 322.52% |
US
|
|
| - | - |
DE
|
